Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $300M and $2B highlights several small-cap companies , including among the market's most expensive names based on valuation grades. Seeking Alpha's valuation grade compares how expensive or cheap a stock is relative to others in its specific sector. The score is calculated using a comprehensive combination of ...
Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $300M and $2B highlights several small-cap companies , including among the market's most expensive names based on valuation grades. Seeking Alpha's valuation grade compares how expensive or cheap a stock is relative to others in its specific sector. The score is calculated using a comprehensive combination of underlying valuation metrics—including P/E, PEG, EV/Sales, EV/EBITDA, EV/EBIT, Price/Sales, Price/Book, Price/Cash Flow, and dividend yield—factoring in both current and forward estimates. The overall valuation grade is derived from a comparison of all underlying metrics and reflects how attractively the stock is priced compared to its sector peers. Most expensive U.S. healthcare stock by valuation grade (market cap between $300M and $2B ): Biohaven ( BHVN ) : Valuation Grade F Greenwich LifeSciences ( GLSI ) : Valuation Grade F HealthStream ( HSTM ) : Valuation Grade F Immix Biopharma ( IMMX ) : Valuation Grade F IRADIMED CORPORATION ( IRMD ) : Valuation Grade F Mesa Laboratories ( MLAB ) : Valuation Grade F Sana Biotechnology ( SANA ) : Valuation Grade F SELLAS Life Sciences Group ( SLS ) : Valuation Grade F Savara ( SVRA ) : Valuation Grade F Trevi Therapeutics ( TRVI ) : Valuation Grade F More on Biohaven, Greenwich Lifesciences, etc. Sellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL Readout Biohaven: Despite Today's Gains, I Remain Skeptical Savara: The Rare Disease Funnel Is Becoming A Commercial Asset Immix Biopharma prices $150M stock offering at $8.94/share Immix rises after mid-stage trial data for AL amyloidosis therapy
With major indices flirting with historically stretched valuations and inflation still nibbling at household budgets, dividend-paying stocks under $40 are getting a fresh look from retail investors who want income without overpaying for it. A sub-$40 entry point can be the difference between a position that earns its keep and one that locks up capital. ... 1 Legally Protected Monopoly Yielding Ove...
With major indices flirting with historically stretched valuations and inflation still nibbling at household budgets, dividend-paying stocks under $40 are getting a fresh look from retail investors who want income without overpaying for it. A sub-$40 entry point can be the difference between a position that earns its keep and one that locks up capital. ... 1 Legally Protected Monopoly Yielding Over 4% That Is Structurally Primed to Make Patient Investors Richer
In early trading on Tuesday, shares of Hewlett Packard Enterprise topped the list of the day's best performing components of the S&P 500 index, trading up 27.2%. Year to date, Hewlett Packard Enterprise Co registers a 149.0% gain. And the worst performing S&P 500 compo
In early trading on Tuesday, shares of Hewlett Packard Enterprise topped the list of the day's best performing components of the S&P 500 index, trading up 27.2%. Year to date, Hewlett Packard Enterprise Co registers a 149.0% gain. And the worst performing S&P 500 compo
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Suncor Energy Inc (Symbol: SU) will trade ex-dividend, for its quarterly dividend of $0.60, payable on 6/25/26. As a percentage of SU's recent stock price of $64.55, this dividend works out to approximat
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Suncor Energy Inc (Symbol: SU) will trade ex-dividend, for its quarterly dividend of $0.60, payable on 6/25/26. As a percentage of SU's recent stock price of $64.55, this dividend works out to approximat
BING-JHEN HONG/iStock Editorial via Getty Images Investment Thesis The month of June 2026 is shaping up to be an interesting one for Nvidia Corporation ( NVDA ), with a unique paradox emerging around the company’s stock. For one thing, Nvidia is the clear leader in the AI industry, solidifying its top spot with an astronomical market cap of $5.1 trillion. Plus, a few days ago, CEO Jensen Huang sha...
BING-JHEN HONG/iStock Editorial via Getty Images Investment Thesis The month of June 2026 is shaping up to be an interesting one for Nvidia Corporation ( NVDA ), with a unique paradox emerging around the company’s stock. For one thing, Nvidia is the clear leader in the AI industry, solidifying its top spot with an astronomical market cap of $5.1 trillion. Plus, a few days ago, CEO Jensen Huang shared some exciting news with the market about plans to enter the PC market with RTX Spark chips. But on the other hand, skeptics keep making bold claims more than ever, defending the idea that the AI bubble is about to burst. The result is two camps of irreconcilable sides, whose questions revolve around the hyperscalers’ CapEx cycle. Currently, there is a lot of skepticism in the market, with concerns about whether the growth in CapEx spending by IT giants will lead to unjustified multi-billion-dollar expenditures, since the monetization of AI agents may turn out to be considerably worse than that of traditional software. Moreover, current conditions are exacerbated by the geopolitical agenda, including ongoing conflict surrounding Iran, resulting in high oil prices that are fueling rising inflation expectations. A scenario of potential macroeconomic collapse, further escalation of military conflict, short-term market volatility, all obscure the main fundamental truth. Inertia of fear amplifies irrational investor thinking, leading them to overlook Blackwell’s pre-sales, whereas the order backlog projects $1 trillion in revenue by 2027. I regret to disappoint those investors who are selling NVDA shares based on market overheating concerns. Anything that might happen in the foreseeable future to drive down the company’s market value will be a rare gift, and not for sellers, rather for buyers who will benefit in the long run from the real scale of the economic transformation driven by AI. NVDA’s Growth Drivers Despite Record Market Capitalization Nvidia’s strategy is built ar...
BING-JHEN HONG/iStock Editorial via Getty Images Investment Thesis The month of June 2026 is shaping up to be an interesting one for Nvidia Corporation ( NVDA ), with a unique paradox emerging around the company’s stock. For one thing, Nvidia is the clear leader in the AI industry, solidifying its top spot with an astronomical market cap of $5.1 trillion. Plus, a few days ago, CEO Jensen Huang sha...
BING-JHEN HONG/iStock Editorial via Getty Images Investment Thesis The month of June 2026 is shaping up to be an interesting one for Nvidia Corporation ( NVDA ), with a unique paradox emerging around the company’s stock. For one thing, Nvidia is the clear leader in the AI industry, solidifying its top spot with an astronomical market cap of $5.1 trillion. Plus, a few days ago, CEO Jensen Huang shared some exciting news with the market about plans to enter the PC market with RTX Spark chips. But on the other hand, skeptics keep making bold claims more than ever, defending the idea that the AI bubble is about to burst. The result is two camps of irreconcilable sides, whose questions revolve around the hyperscalers’ CapEx cycle. Currently, there is a lot of skepticism in the market, with concerns about whether the growth in CapEx spending by IT giants will lead to unjustified multi-billion-dollar expenditures, since the monetization of AI agents may turn out to be considerably worse than that of traditional software. Moreover, current conditions are exacerbated by the geopolitical agenda, including ongoing conflict surrounding Iran, resulting in high oil prices that are fueling rising inflation expectations. A scenario of potential macroeconomic collapse, further escalation of military conflict, and short-term market volatility all obscure the main fundamental truth. Inertia of fear amplifies irrational investor thinking, leading them to overlook Blackwell’s pre-sales, whereas the order backlog projects $1 trillion in revenue by 2027. I regret to disappoint those investors who are selling NVDA shares based on market overheating concerns. Anything that might happen in the foreseeable future to drive down the company’s market value will be a rare gift, and not for sellers, but rather for buyers who will benefit in the long run from the real scale of the economic transformation driven by AI. NVDA’s Growth Drivers Despite Record Market Capitalization Nvidia’s strategy is b...
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Ryerson Holding Corp (Symbol: RYZ) will trade ex-dividend, for its quarterly dividend of $0.1875, payable on 6/18/26. As a percentage of RYZ's recent stock price of $28.50, this dividend works out to app
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Ryerson Holding Corp (Symbol: RYZ) will trade ex-dividend, for its quarterly dividend of $0.1875, payable on 6/18/26. As a percentage of RYZ's recent stock price of $28.50, this dividend works out to app
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Liberty Energy Inc (Symbol: LBRT) will trade ex-dividend, for its quarterly dividend of $0.09, payable on 6/18/26. As a percentage of LBRT's recent stock price of $30.33, this dividend works out to appro
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Liberty Energy Inc (Symbol: LBRT) will trade ex-dividend, for its quarterly dividend of $0.09, payable on 6/18/26. As a percentage of LBRT's recent stock price of $30.33, this dividend works out to appro
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Qualcomm Inc (Symbol: QCOM) will trade ex-dividend, for its quarterly dividend of $0.92, payable on 6/25/26. As a percentage of QCOM's recent stock price of $232.17, this dividend works out to approximat
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Qualcomm Inc (Symbol: QCOM) will trade ex-dividend, for its quarterly dividend of $0.92, payable on 6/25/26. As a percentage of QCOM's recent stock price of $232.17, this dividend works out to approximat
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Saratoga Investment Corp New (Symbol: SAR) will trade ex-dividend, for its monthly dividend of $0.25, payable on 6/23/26. As a percentage of SAR's recent stock price of $22.62, this dividend works out to
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, Saratoga Investment Corp New (Symbol: SAR) will trade ex-dividend, for its monthly dividend of $0.25, payable on 6/23/26. As a percentage of SAR's recent stock price of $22.62, this dividend works out to
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, SLM Corp. (Symbol: SLM) will trade ex-dividend, for its quarterly dividend of $0.13, payable on 6/15/26. As a percentage of SLM's recent stock price of $22.15, this dividend works out to approximately 0.
Looking at the universe of stocks we cover at Dividend Channel, on 6/4/26, SLM Corp. (Symbol: SLM) will trade ex-dividend, for its quarterly dividend of $0.13, payable on 6/15/26. As a percentage of SLM's recent stock price of $22.15, this dividend works out to approximately 0.
Berkshire Hathaway (NYSE: BRKA) (NYSE: BRKB) owns dozens of well-known businesses as well as a stock portfolio worth about $300 billion. But over the past few years, the biggest source of frustration among investors hasn't had anything to do with either of those things. It's the hundreds of billions of dollars in cash on Berkshire's balance sheet that is earning low-single-digit returns, while the...
Berkshire Hathaway (NYSE: BRKA) (NYSE: BRKB) owns dozens of well-known businesses as well as a stock portfolio worth about $300 billion. But over the past few years, the biggest source of frustration among investors hasn't had anything to do with either of those things. It's the hundreds of billions of dollars in cash on Berkshire's balance sheet that is earning low-single-digit returns, while the S&P 500 has gained 15% or more in the typical year. It looks like Berkshire's new CEO, Greg Abel, is putting some of that to work. Berkshire has announced two major investments in just two days. And while by themselves, they aren't likely to be needle-movers, if this pattern continues, it could be a big deal for the company and its investors. Image source: Getty Images. Continue reading
ADragan/iStock via Getty Images Oculis Investment Overview The stock of Oculis Holding AG ( OCS ), a Zug, Switzerland headquartered biotech focused on the treatment of neuro-ophthalmic and ophthalmic diseases, was in freefall yesterday, dropping >35% for the day, from ~$23 per share to $15 per share, as the market digested topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 e...
ADragan/iStock via Getty Images Oculis Investment Overview The stock of Oculis Holding AG ( OCS ), a Zug, Switzerland headquartered biotech focused on the treatment of neuro-ophthalmic and ophthalmic diseases, was in freefall yesterday, dropping >35% for the day, from ~$23 per share to $15 per share, as the market digested topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema ("DME"), released late Friday. Oculis stock is now down >50% on a 5-day basis, and its market cap has fallen to ~$830m pre-market today. According to an Oculis press release : The DIAMOND (DIAbetic Macular edema patients ON a Drop) program consisted of two Phase 3, double-masked, randomized, multi-center trials to evaluate the efficacy and safety of OCS-01 eye drops in patients with DME following 52 weeks of treatment. Over 800 patients were enrolled across both pivotal trials at 119 investigational sites throughout the United States and several other countries. The primary endpoint, mean change in best corrected visual acuity early treatment diabetic retinopathy study ("BCVA ETDRS") letter score at Week 52, was not met in both trials. The secondary endpoint of retinal thickness, as measured by OCT, showed a substantial and persistent reduction with OCS-01 vs vehicle at all visits in DIAMOND-2 and at all visits except Week 52 in DIAMOND-1. The key secondary endpoint of the proportion of patients with ≥15-letter gain in BCVA was not met in both trials. Oculis had formerly communicated that if results from the studies were positive, it would submit a New Drug Application requesting an FDA approval for OCS-01 by the end of this year, but in Friday's press release, a statement reads: Based on the results, at this time, Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in DME Analysis - Significant Miss Scuppers Innovative Therapies' Approval Shot Biotech companies are often unwilling to give up on a lead asset ev...